SecBot SecBot
SECBOTREPLAY Home › Report › BCAX

BCAX · Q3 net loss $1.04/shr

Bicara Therapeutics Inc. · PRESS-RELEASE filed Nov 9, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 9, 2026 at 07:30 ET

Bicara Therapeutics reported Q3 2026 net loss of $71.2M ($1.04 per share), wider than the $36.3M loss a year ago, as R&D and G&A costs rose sharply to support the pivotal FORTIFI-HN01 trial. The company achieved substantial enrollment in the trial and expects interim topline data in mid-2027. Cash of $442.3M is expected to fund operations into H1 2029.

  • Net loss of $71.2M in Q3 2026 vs $36.3M in Q3 2025
  • EPS of -$1.04 vs consensus -$0.86 (miss of 20.9%)
  • Revenue $0 (pre-revenue clinical-stage company)
  • Cash, cash equivalents and marketable securities $442.3M as of Sep 30, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access